Evidence map›Paper›PMID 36631133›Full record

ReviewEuropean respiratory review : an official journal of the European Respiratory Society2023

Endotyping COPD: hypoxia-inducible factor-2 as a molecular "switch" between the vascular and airway phenotypes?

Oleh Myronenko, Vasile Foris, Slaven Crnkovic, Andrea Olschewski, Sonia Rocha, Mark R Nicolls, Horst Olschewski

Open access · diamondAbstract readReview
In one paragraph

Review in European respiratory review : an official journal of the European Respiratory Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. International journal of chronic obstructive pulmonary disease · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Pulmonary veno-occlusive disease: a clinical review.Breathe (Sheffield, England) · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Oleh MyronenkoDivision of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0001-5221-7218
Vasile ForisDivision of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Slaven CrnkovicLudwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
Andrea OlschewskiLudwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.ORCID https://orcid.org/0000-0002-8189-3634
Sonia RochaDepartment of Molecular Physiology and Cell Signalling, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK.
Mark R NicollsDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.ORCID https://orcid.org/0000-0001-9473-7422
Horst OlschewskiDivision of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria horst.olschewski@medunigraz.at.
Medical University of Graz · ATStanford University · USUniversity of Liverpool · GB

Funding

Stanford Career Development Program in Omics of Lung DiseasesK12HL120001 · NHLBI · STANFORD UNIVERSITY · PI NICOLLS, MARK ROBERT, RABINOVITCH, MARLENE · 2013 to 2017
$1.3M
Austrian Science Fund FWF DOC 129NHLBI NIH HHS K12 HL120001Wellcome Trust 206293/Z/17/Z
6 · The paper itself

Abstract

COPD is a heterogeneous disease with multiple clinical phenotypes. COPD endotypes can be determined by different expressions of hypoxia-inducible factors (HIFs), which, in combination with individual susceptibility and environmental factors, may cause predominant airway or vascular changes in the lung. The pulmonary vascular phenotype is relatively rare among COPD patients and characterised by out-of-proportion pulmonary hypertension (PH) and low diffusing capacity of the lung for carbon monoxide, but only mild-to-moderate airway obstruction. Its histologic feature, severe remodelling of the small pulmonary arteries, can be mediated by HIF-2 overexpression in experimental PH models. HIF-2 is not only involved in the vascular remodelling but also in the parenchyma destruction. Endothelial cells from human emphysema lungs express reduced HIF-2α levels, and the deletion of pulmonary endothelial

Indexed as

Basic Helix-Loop-Helix ProteinsPulmonary Disease, Chronic ObstructiveAnimalsEmphysemaEndothelial CellsEndothelial PAS Domain-Containing Protein 1HumansHypertension, PulmonaryHypoxiaMicePulmonary EmphysemaBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1

Identifiers

PMID36631133
PMCPMC9879331
OpenAlexW4315647708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.